Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.

异环磷酰胺 阿霉素 医学 养生 顺铂 化疗 丝裂霉素C 泌尿科 外科 内科学 胃肠病学
作者
J H Edmonson,Louise Ryan,Ronald H. Blum,John S. Brooks,Masanori Shiraki,Stephen Frytak,David Parkinson
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:11 (7): 1269-1275 被引量:515
标识
DOI:10.1200/jco.1993.11.7.1269
摘要

PURPOSE This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin. PATIENTS AND METHODS Between December 1987 and July 1990, 279 patients with histologically confirmed sarcomas were enrolled to receive treatment A (doxorubicin 80 mg/m2), treatment B (ifosfamide 7.5 g/m2 plus doxorubicin 60 mg/m2), or treatment C (mitomycin 8 mg/m2 plus doxorubicin 40 mg/m2 plus cisplatin 60 mg/m2). RESULTS Of 262 assessable patients, 74 (29%) achieved objective tumor regression. Objective regression occurred in 20% of the 90 patients who received doxorubicin alone (complete remission [CR] rate, 2%), in 34% of the 88 who received ifosfamide plus doxorubicin (CR rate, 3%), and in 32% of the 84 who received mitomycin plus doxorubicin plus cisplatin (CR rate, 7%). With grade 3 or greater myelosuppression in 53% of group A, 80% of group B, and 55% of group C, regimen B was significantly more myelosuppressive than either regimen A or C (P = .01) with two, three, and one treatment-related deaths, respectively. Synovial sarcomas were responsive to ifosfamide plus doxorubicin, especially among patients younger than 40 years of age. CONCLUSION Ifosfamide plus doxorubicin produced a significantly higher regression rate (P = .03) than did doxorubicin alone; however, this was achieved at a level of myelosuppression significantly more intense than that produced by the single agent or by the three-drug combination. Mitomycin, doxorubicin, and cisplatin also appeared to be more active than the single agent; however, at a myelosuppression level similar to that of doxorubicin alone, this trend (P = .07) did not attain the usual level for significance. No significant survival differences were observed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
立na应助张凌霄采纳,获得20
1秒前
嘻嘻嘻完成签到,获得积分20
1秒前
2秒前
2秒前
英俊的铭应助云山枫叶采纳,获得10
2秒前
3秒前
kabayi完成签到 ,获得积分10
3秒前
3秒前
李友健发布了新的文献求助200
3秒前
3秒前
脑洞疼应助活力涟妖采纳,获得10
3秒前
小愚发布了新的文献求助10
3秒前
嘻嘻嘻发布了新的文献求助10
4秒前
田田发布了新的文献求助10
4秒前
林克关注了科研通微信公众号
4秒前
爆米花应助帅气青旋采纳,获得10
4秒前
5秒前
6秒前
6秒前
6秒前
7秒前
7秒前
合适的语雪完成签到,获得积分10
7秒前
虚幻阁完成签到 ,获得积分10
8秒前
科研民工发布了新的文献求助10
8秒前
8秒前
无极微光应助Dreamheyheyhey采纳,获得20
9秒前
英姑应助温暖的乌龟采纳,获得50
9秒前
SciGPT应助匿名的薯片采纳,获得200
9秒前
111发布了新的文献求助10
10秒前
11秒前
11秒前
辛勤夜柳发布了新的文献求助10
12秒前
万能图书馆应助Whitney采纳,获得10
12秒前
风清扬发布了新的文献求助10
13秒前
qingqiu发布了新的文献求助10
14秒前
蓝天发布了新的文献求助10
15秒前
Samuel发布了新的文献求助10
15秒前
16秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Arthritis and Related Conditions, An Issue of Orthopedic Clinics 1000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
ズームレンズの光学設計に関する研究 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7287107
求助须知:如何正确求助?哪些是违规求助? 8907088
关于积分的说明 18849872
捐赠科研通 6956155
什么是DOI,文献DOI怎么找? 3208471
关于科研通互助平台的介绍 2378480
邀请新用户注册赠送积分活动 2184203